| Market Cap | 396.20M | P/E | - | EPS this Y | -8.90% | Ern Qtrly Grth | - |
| Income | -109.63M | Forward P/E | -3.25 | EPS next Y | -12.40% | 50D Avg Chg | 22.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 99.00% |
| Dividend | N/A | Price/Book | 2.25 | EPS next 5Y | - | 52W High Chg | -2.00% |
| Recommedations | 1.70 | Quick Ratio | 9.04 | Shares Outstanding | 57.27M | 52W Low Chg | 344.00% |
| Insider Own | 3.63% | ROA | -35.47% | Shares Float | 29.25M | Beta | 2.04 |
| Inst Own | 100.43% | ROE | -56.40% | Shares Shorted/Prior | 8.83M/8.58M | Price | 9.72 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 367,814 | Target Price | 27.43 |
| Oper. Margin | - | Earnings Date | Nov 5 | Volume | 206,904 | Change | 7.05% |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| JP Morgan | Overweight | Aug 8, 24 |
| HC Wainwright & Co. | Buy | Aug 7, 24 |
| Oppenheimer | Outperform | Aug 7, 24 |
| HC Wainwright & Co. | Buy | Jun 4, 24 |
| HC Wainwright & Co. | Buy | May 15, 24 |
| HC Wainwright & Co. | Buy | May 9, 24 |
| Goldman Sachs | Buy | Apr 2, 24 |
| Oppenheimer | Outperform | Mar 12, 24 |
| HC Wainwright & Co. | Buy | Mar 12, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zojwalla Naseem | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Jan 25 | Option | 7.02 | 20,000 | 140,400 | 66,664 | 01/29/24 |
| Kovacs Shane William Charles | CH. OPERATING & FINA.. CH. OPERATING & FINANCIAL OFF. | Jan 12 | Option | 7.02 | 50,000 | 351,000 | 484,987 | 01/16/24 |
| Graham G. Walmsley | Director Director | Sep 12 | Buy | 13.15 | 640,000 | 8,416,000 | 1,800,000 | 12/18/23 |
| Kovacs Shane William Charles | CH. OPERATING & FINA.. CH. OPERATING & FINANCIAL OFF. | Dec 12 | Option | 7.02 | 10,000 | 70,200 | 434,987 | 12/12/23 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Dec 11 | Option | 7.02 | 2,900 | 20,358 | 46,664 | 12/12/23 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Dec 06 | Option | 7.02 | 13,100 | 91,962 | 43,764 | 12/07/23 |
| Harmon Cyrus | Director Director | Nov 30 | Sell | 12.57 | 25,000 | 314,250 | 926,283 | 12/01/23 |
| Harmon Cyrus | Director Director | Nov 20 | Sell | 14.38 | 8,181 | 117,643 | 951,283 | 11/22/23 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Nov 20 | Sell | 14.68 | 14,556 | 213,682 | 30,664 | 11/22/23 |
| Myles David C. | CH. DISCOV. & NON-CL.. CH. DISCOV. & NON-CLIN DEV OFF | Nov 20 | Sell | 14.69 | 13,629 | 200,210 | 574,099 | 11/22/23 |
| Bohen Sean | PRESIDENT AND CEO PRESIDENT AND CEO | Nov 20 | Sell | 14.68 | 57,225 | 840,063 | 144,925 | 11/22/23 |
| Kovacs Shane William Charles | CH. OPERATING & FINA.. CH. OPERATING & FINANCIAL OFF. | Nov 20 | Sell | 14.66 | 18,742 | 274,758 | 424,987 | 11/22/23 |
| Myles David C. | CH. DISCOV. & NON-CL.. CH. DISCOV. & NON-CLIN DEV OFF | Nov 08 | Sell | 17.61 | 200 | 3,522 | 561,270 | 11/13/23 |
| Myles David C. | CH. DISCOV. & NON-CL.. CH. DISCOV. & NON-CLIN DEV OFF | Nov 01 | Sell | 15.96 | 10,541 | 168,234 | 561,470 | 11/03/23 |
| Harmon Cyrus | Director Director | Oct 31 | Sell | 13.85 | 30,000 | 415,500 | 943,714 | 11/02/23 |
| Myles David C. | CH. DISCOV. & NON-CL.. CH. DISCOV. & NON-CLIN DEV OFF | Sep 19 | Sell | 12.67 | 20,000 | 253,400 | 572,011 | 09/21/23 |
| Harmon Cyrus | Director Director | Aug 31 | Sell | 10.49 | 25,000 | 262,250 | 998,714 | 09/05/23 |
| Harmon Cyrus | Director Director | Aug 16 | Sell | 10.14 | 15,000 | 152,100 | 1,023,714 | 08/17/23 |
| Harmon Cyrus | Director Director | Jun 08 | Sell | 6.30 | 10,000 | 63,000 | 1,038,714 | 06/09/23 |
| Harmon Cyrus | Director Director | Jun 05 | Sell | 6.17 | 10,000 | 61,700 | 1,048,714 | 06/07/23 |
| Horn Kinney | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Feb 10 | Option | 2.06 | 5,251 | 10,817 | 7,709 | 02/14/22 |
| Horn Kinney | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Jan 10 | Option | 2.06 | 5,251 | 10,817 | 7,709 | 01/11/22 |
| Horn Kinney | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Jan 10 | Sell | 6.85 | 5,251 | 35,969 | 2,458 | 01/11/22 |
| BVF PARTNERS L P/IL | Director Director | Nov 30 | Buy | 9.39 | 739,675 | 6,945,548 | 471,350 | 12/02/21 |
| Bohen Sean | PRESIDENT AND CEO PRESIDENT AND CEO | Oct 14 | Option | 4.82 | 5,000 | 24,100 | 57,514 | 10/15/21 |
| Bohen Sean | PRESIDENT AND CEO PRESIDENT AND CEO | Oct 14 | Sell | 30.8 | 5,000 | 154,000 | 52,514 | 10/15/21 |
| Horn Kinney | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Oct 11 | Option | 2.06 | 5,251 | 10,817 | 7,041 | 10/12/21 |
| Horn Kinney | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Oct 11 | Sell | 27.83 | 5,251 | 146,135 | 1,790 | 10/12/21 |